CYTH2

Across TCGA pan-cancer cohorts, CYTH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYTH2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYTH2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CYTH2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where CYTH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.989	0.926	.031	12	view →
LUAD	OS	Tertile	III,IV	0.332	0.819	.016	5	view →
LSCC	OS	Quartile	All	0.877	0.969	.024	5	view →
PDAC	DFS	Median	II,III,IV	0.856	0.666	.032	3	view →
CCRCC	OS	Quartile	III,IV	0.785	0.466	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYTH2–HNSC (OS)

Open the HNSC breakdown →